SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced its participation in two upcoming conferences.
Mick Farrell, chief executive officer and chair of the board, and Brett Sandercock, chief financial officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023, beginning at approximately 10:50 a.m. (Eastern Daylight Time) at the Sheraton New York Times Square in New York, NY.
Rob Douglas, president and chief operating officer, and Amy Wakeham, chief communications and investor relations officer, will participate in a fireside chat at the Bank of America Global Healthcare Conference 2023 on Thursday, September 14, 2023, beginning at approximately 4:45 p.m. (British Summer Time) at Bank of America Financial Centre in London, England.
More information about these events, including access to the live, audio-only webcasts, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replays will be available approximately 24 hours after the live webcasts end and will be accessible for the following 180 days.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
For investors | For media |
+1 858-836-5000 | +1 858-289-7272 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$214.53 |
Daily Change: | 0.54 0.25 |
Daily Volume: | 1,447,016 |
Market Cap: | US$31.490B |
April 03, 2025 January 30, 2025 October 24, 2024 September 30, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load